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Abstract
Background The multiplicity of issues, including uncer-
tainty and ethical dilemmas, and policies involved in
appraising interventions for rare diseases suggests that
multicriteria decision analysis (MCDA) based on a holistic
definition of value is uniquely suited for this purpose. The
objective of this study was to analyze and further develop a
comprehensive MCDA framework (EVIDEM) to address
rare disease issues and policies, while maintaining its
applicability across disease areas.
Methods Specific issues and policies for rare diseases
were identified through literature review. Ethical and
methodological foundations of the EVIDEM framework
v3.0 were systematically analyzed from the perspective of
these issues, and policies and modifications of the frame-
work were performed accordingly to ensure their
integration.
Results Analysis showed that the framework integrates
ethical dilemmas and issues inherent to appraising inter-
ventions for rare diseases but required further integration of
specific aspects. Modification thus included the addition of
subcriteria to further differentiate disease severity, disease-
specific treatment outcomes, and economic consequences
of interventions for rare diseases. Scoring scales were
further developed to include negative scales for all com-
parative criteria. A methodology was established to
incorporate context-specific population priorities and poli-
cies, such as those for rare diseases, into the quantitative
part of the framework. This design allows making more
explicit trade-offs between competing ethical positions of
fairness (prioritization of those who are worst off), the goal
of benefiting as many people as possible, the imperative to
help, and wise use of knowledge and resources. It also
allows addressing variability in institutional policies
regarding prioritization of specific disease areas, in addi-
tion to existing uncertainty analysis available from
EVIDEM.
Conclusion The adapted framework measures value in its
widest sense, while being responsive to rare disease issues
and policies. It provides an operationalizable platform to
integrate values, competing ethical dilemmas, and uncer-
tainty in appraising healthcare interventions.
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Key Points for Decision Makers
The adapted EVIDEM framework provides an
operationalizable platform to integrate individual
and social values, competing ethical dilemmas, and
uncertainty, which are particularly challenging in
appraising interventions for rare diseases.
The addition of subcriteria to further differentiate
disease severity, disease-specific treatment outcomes
and economic consequences of interventions,
inclusion of negative scoring scales for all
comparative criteria, and integration of a
methodology to further incorporate context-specific
population priorities and policies makes the
EVIDEM framework particularly responsive to rare
diseases, while maintaining its applicability across
disease areas.
Additionally, a method was developed to address
variability in country or institution policies with
respect to prioritization of specific disease areas.
1 Introduction
Appraising the value of interventions for rare diseases
raises a number of difficult issues. Many of these condi-
tions are severe, chronic, progressive, and life-threatening,
with multiple medical, psychological, and social conse-
quences [1, 2]. Their rareness is a major barrier to devel-
oping targeted therapeutic interventions due to both
economic and scientific constraints. As a consequence,
unmet needs remain significant and widespread [3].
Uncertainty is also a critical issue in rare diseases, and
includes limitations in our understanding of natural history
[4] as well as challenges in obtaining high-quality epi-
demiological [5–8], clinical [9, 10], and economic data. In
addition to uncertainty on evidence, there is variability in
country or institution policies and across stakeholders on
the values at stake. Regulatory policies to support the
development of interventions for rare diseases are in place
[11, 12] but, once approved, appraising these often highly-
priced products for reimbursement is a challenge for health
technology assessment (HTA) [13–15]. Some agencies
acknowledge that their standard appraisal approaches need
to be modified for orphan products [13], and a few have
developed explicit approaches, including the National
Institute for Health and Care Excellence (NICE) Interim
Process for Highly Specialized Technologies (HST) [16]
and the Ontario Public Drugs Program framework [17].
The multiplicity of issues involved in appraising inter-
ventions for rare diseases, as highlighted in the NICE
interim HST process [16], suggests that multicriteria
decision analysis (MCDA)-based approaches that apply a
holistic definition of value are uniquely suited for this
purpose. MCDA makes explicit which criteria are used and
how they are balanced in decision making. Several multi-
criteria approaches designed for appraising interventions
for rare diseases have been proposed, suggesting different
sets of decision criteria that were selected based on various
approaches [18–20]. To be justifiable, decisions regarding
healthcare interventions, and thus the criteria included in a
multicriteria framework, must be based on reasons that
reflect society’s ethical principles and substantive values,
concepts such as fairness and efficiency [21, 22], while the
decision-making process must reflect procedural values
such as transparency, accountability, and participation [21]
to help legitimize decisions by upholding procedural jus-
tice [21, 23, 24]. Thus, there is a need for a comprehensive
appraisal framework that features decision criteria that are
selected based on ethical principles (i.e. social substantive
values) and reflects social procedural values.
EVIDEM is an open-source, collaboratively-developed
[25–30] MCDA framework designed to appraise the
holistic value of healthcare interventions [31]. It has been
tested [26, 27, 32, 33] and implemented [34, 35] in various
real-world decision-making settings. The EVIDEM
framework v3.0 is structured around the key objectives
(domains) that govern healthcare decision making and
define the holistic value of interventions, i.e. to optimize
the health of patients, populations, and healthcare systems.
Attainment of these objectives is assessed using opera-
tionalizable criteria, each of which is rooted in established
ethical positions [36, 37], including deontology (imperative
to help, beneficence, nonmaleficence) [38–41], utilitarian-
ism (greatest good for the greatest number) [42, 43], dis-
tributive justice and fairness (prioritize those who are worst
off) [43, 44], and virtue ethics and practical wisdom [45].
The framework was designed to meet MCDA design
principles, i.e. each criterion must make a unique contri-
bution to the value of an intervention, while the criteria set
needs to be complete, operationalizable, and free of
redundancies and mutual dependencies [46]. Objectives are
classified into normative and feasibility domains. In the
quantitative part of the framework, criteria are weighted
and scored to obtain a numerical measure of the value of an
intervention (Value Estimate). The qualitative part captures
the impact on value of those criteria that are difficult to
quantify. Key procedural values underpinning EVIDEM
are transparency, pragmatism, and participatory decision
making [25–27].
Because of its holistic definition of value, explicit
rootedness in ethical principles and real-world application,
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the EVIDEM framework was selected for this study to be
analyzed and further developed into a comprehensive
MCDA approach that addresses rare disease issues and
policies, while maintaining its applicability across disease
areas.
2 Methodology
2.1 Identification of Specific Issues Raised by Rare
Diseases
A systematic literature review was carried out to identify
issues in rare diseases that potentially impact on value
appraisal as well as relevant current or proposed regulatory
and reimbursement policies. Full-text publications related
to disease impact (including size of population), context of
interventions, clinical outcomes, costs, ethical issues, and
licensing and reimbursement policies were included. Case
reports and articles of clinical focus describing the natural
history, clinical presentation, or treatment of specific rare
diseases were excluded. The principal sources of infor-
mation were peer-reviewed publications identified from the
PubMed/MEDLINE databases (published from January
2003 to September 2013). Using keywords such as ‘orphan
disease’ and ‘rare disorder, the PubMed/MEDLINE sear-
ches yielded 6525 citations, 115 of which were reviewed in
full text, and 41 [2–10, 17–20, 47–74] included in the
analysis, including five publications describing current or
proposed appraisal frameworks for rare diseases [17–20,
68]. Additionally, websites of major regulatory and HTA
agencies, rare disease organizations and networks (e.g.
ORPHANET, EUROPLAN, Office for Rare Disease
Research), and bibliographies of key publications were
searched for relevant information.
The selected publications were analyzed to identify
issues pertaining to value appraisal. The relevant issues
were classified by the decision criterion to which they
pertain, using the criteria definitions and the structure of
the EVIDEM framework as an analytical tool.
2.2 Analysis and Adaptation of the EVIDEM
Framework from the Perspective of Issues
Raised by Rare Diseases
Ethical and methodological foundations of the EVIDEM
framework v3.0 [36, 37] were analyzed on a criterion-
by-criterion basis to assess their relevance and implica-
tions from the perspective of issues raised by rare dis-
eases. This analysis was used to determine whether a
modification of the framework was required to enhance
its usefulness for appraising interventions for rare
diseases, while preserving its applicability across disease
areas. Potential modifications included:
• definition of subcriteria to allow a more differentiated
assessment of specific criteria;
• further development of scoring scales;
• structural transformation of the framework by moving
criteria that are assessed qualitatively into the quanti-
tative part of the framework to integrate context-
specific policies and priorities.
3 Results
The adapted EVIDEM framework is shown in Fig. 1 (see
Online Resource 1 for the full framework). For the
quantitative part of the framework (a), hierarchical point
allocation was selected as the primary weight elicitation
technique, a method that allows direct expression of
personal values and makes explicit the trade-offs that
need to be made across the criteria [75]. As in the original
framework, weighting is performed independently of the
intervention appraised (generic weighting), with the
exception of the subcriteria defining intervention out-
comes, for which disease-specific weights are elicited to
define the relative weight of each outcome as part of the
Comparative Effectiveness criterion. Evaluators score the
intervention with respect to each criterion using con-
structed, cardinal scoring scales, designed to measure
their judgments on the evidence presented. These scales
include scores of zero, corresponding to situations where
the intervention has no value with respect to a criterion.
The framework was adapted to include negative scores for
all comparative criteria to reflect worse outcomes or
economic consequences than comparators, which are rel-
evant to rare diseases, but also in general for fair
appraisal of interventions. The impacts of contextual cri-
teria on the value of the intervention are considered
qualitatively using a separate tool (b).
Criteria-specific analyses and adaptations are summa-
rized in Table 1 and are reported below.
3.1 Normative Universal Objectives
and Quantitative Criteria
These criteria are assessed quantitatively because they are
universally quantifiable in the sense that their achievement
can be assessed across healthcare systems on scales for
which the high and low ends are a priori agreed upon [37].
The objective of addressing areas of high therapeutic
need covers three criteria:
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• Disease Severity: Grounded in the ethical imperative to
alleviate suffering in those who are worst off (theory of
justice), interventions for more severe diseases have
greater value than those for less severe diseases [36].
Rare diseases can have multiple impacts on patients,
causing morbidity, disability, reduced quality of life
(QoL), and shorter life expectancy [1, 2, 69].
Approximately half of these conditions begin in
childhood and many cause disabilities [1], thus posing
a high burden on caregivers, usually family members
[69], which may have a detrimental impact on their
QoL [1–3]. To allow a more differentiated assessment
of the multiple domains of disease severity potentially
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Fig. 1 Adapted EVIDEM MCDA framework: (a) quantitative MCDA model (with hierarchical structure and weighting method); and
(b) contextual criteria for qualitative appraisal. MCDA multicriteria decision analysis; PRO patient-reported outcome
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introduced, including Effect of Disease on Caregivers’
QoL, which is consistent with other assessment frame-
works, such as the NICE Interim Process for HST [16].
• Size of Population: Based on utility theory, this
criterion aims at alleviating suffering in as many
individuals as possible [36, 37]. Accordingly, a large
population of patients affected represents a high
therapeutic need, which is in agreement with surveys
of the general public revealing that rareness in itself,
apart from other considerations such as disease sever-
ity, is not considered a healthcare priority [51, 52, 63,
66]. Capturing an important aspect of social value, this
criterion needs to be retained in an appraisal framework
that is to be applied across different disease areas.
Review of epidemiological data on rare diseases [76]
suggested an adaptation of the scoring scale to better
reflect the wide range of possible disease incidence/
prevalence rates, extending from very common (preva-
lence[5 in 100) to very rare diseases (\5 in 100,000).
• Unmet Needs, whereby a condition for which current
interventions have many and serious limitations regard-
ing their effectiveness, safety, tolerability, and QoL
impact represents high need [37]. This criterion is
highly relevant for rare diseases, where major thera-
peutic limitations persist and few interventions targeted
for a specific condition are available [3].
The objective of providing large improvements in health
outcomes is rooted in deontology (i.e. duty- or rule-based
ethics) and outlined in the Hippocratic Oath as well in the
principles of beneficence, nonmaleficence, and respect of




• Comparative patient-reported outcomes (PROs)
One of the issues in rare diseases pertaining to these
criteria is uncertainty or lack of consensus on the outcomes
that need to be assessed in clinical studies. This issue can
be partially addressed by dividing these criteria into sub-
criteria to represent outcomes specific to the disease, which
will allow appraisers to discuss and differentially weight
the importance (relevance) of each outcome.
The objective of delivering important types of health
benefit is rooted in the ethical imperative to prevent and
eliminate suffering (deontology), and covers two criteria
[36]:
• Type of preventive benefit, whereby preventing a
disease entirely (eradication) is the most important
type of preventive benefit (risk reduction).
• Type of therapeutic benefit, whereby alleviating suffer-
ing entirely (cure) is the most important type of
therapeutic benefit.
Although the vast majority of rare diseases are of
genetic origin [2], and interventions are therefore generally
therapeutic rather than preventive, this design acknowl-
edges the value of both prophylactic and therapeutic
interventions to ensure compatibility of the framework
across therapeutic areas.
Both maximization of health benefits and minimization
of costs are legitimate objectives of healthcare decision
making, rooted in the ethical imperative of making wise
use of scarce resources (practical wisdom) to maximize
health under resource constraints (utilitarianism) [36, 37].
Thus, an intervention’s economic consequences represent
value attributes and are therefore incorporated into a
framework intended to measure value from a holistic per-
spective, as recommended by the UK Government manual
conducting multicriteria decision making [46]. The objec-
tive of producing favorable economic consequences is
addressed with three criteria; for each of these, cost
reduction (or release of resources) is seen as a favorable
economic consequence:
• Comparative cost consequences—cost of intervention:
Net cost of an intervention to the healthcare system in
terms of its acquisition, implementation, maintenance,
and replacement of existing treatments or interventions.
• Comparative cost consequences—other medical costs:
All medical cost consequences of an intervention, apart
from the cost of the intervention itself (e.g. hospital-
ization, specialized care, primary care, long-term care,
adverse event costs).
• Comparative cost consequences—nonmedical costs:
All cost consequences outside the scope of medical
care.
Interventions can affect patients’ medical or nonmedical
expenses through co-payments, travel, and paid caregivers,
as well as impact patients’ and caregivers’ ability to work,
all of which are highly relevant to rare diseases [2, 3, 70],
as well as to many other conditions. Therefore, the adapted
framework includes subcriteria, defined by payer (i.e.
healthcare system, patients), allowing differentiation of
diverse economic consequences and adjustments for
appraisals from different perspectives.
Cost effectiveness combines several criteria already
covered and is therefore not included in the framework, in
line with basic design principles of MCDA to avoid dou-
ble-counting and with other rare disease frameworks [16,
17, 19].
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The objective of reducing uncertainty by grounding
decisions in solid knowledge is covered under two criteria,
both related to practical wisdom [36]:
• Quality of Evidence: This criterion ensures that higher
value is placed on interventions that have a statistically
solid and unbiased scientific evidence base [36, 37, 77].
Responding to the imperative of evidence-based deci-
sion making, this criterion explicitly rewards high-
quality research and development. The rareness of a
condition affects data quality in multiple areas, includ-
ing the burden and natural history of the disease, and
the health and economic consequences of a proposed
therapy [4–8]. For example, designing well-powered,
double-blind, randomized controlled trials (RCTs) is
challenging for rare diseases because patients are few
[9] and effective comparators are often absent [10].
Therefore, real-life studies and modeling can play an
important role for assessing rare disease therapies [17].
Thus, the adapted framework includes subcriteria
representing different fields of research, allowing a
differential assessment of data quality.
• Expert Consensus/Clinical Practice Guidelines
(CPGs): This criterion captures the strength of recom-
mendations for optimal clinical practice based on
expert interpretation of current scientific knowledge
as well as bedside expertise [37]. A strong recommen-
dation in a CPG developed following AGREE princi-
ples [78] raises confidence in the value of an
intervention. For rare diseases, the availability and
quality of CPGs is often limited [55], thus it is
particularly important to capture expert knowledge,
bearing in mind the scarcity of clinical experts and
clinical data [1, 64].
3.2 Transformation of a Generic Qualitative
Criterion into a Quantitative Context-Specific
Criterion: Population Priority and Access
The objective of Addressing Priorities to Increase Fair-
ness/Justice reflects a society’s sense of justice, which may
entail giving priority to certain populations, as defined in
specific societies and healthcare systems [36, 37]. Although
there are various models of distributive justice (e.g. liber-
tarian, communitarian, egalitarian, and utilitarian) [79],
solidarity with those most in need is a key concept [56], as
expressed in surveys of the general European population
[51, 63]. Patients with rare diseases may be seen as a
particularly disadvantaged population as they are often
affected by social isolation [1, 57], delayed diagnosis [1, 3,
72], and inequalities in access to adequate treatment and
care [1]. The disadvantaged status of these patients is
acknowledged in regulatory policies that support research
in orphan diseases [11, 12]. In addition, a number of public
initiatives were launched to improve delivery of healthcare
and social services to patients with rare diseases [80–83].
Although most decision makers consider population
priorities [28], specific priorities may or may not be
explicitly established in the context of a given healthcare
system. Thus, one can distinguish two types of contexts:
• If no population priorities are explicitly established,
this objective cannot be quantitatively operationalized
and must remain in the qualitative part for the
framework for qualitative, general (case-by-case)
consideration.
• If specific population priorities are clearly established,
the framework is adapted to integrate the objective of
addressing priorities into the quantitative part of the
framework, bearing in mind that multiple priorities may
exist in a given context. To operationalize this integra-
tion, each population priority is defined as a criterion:
• priority 1 (e.g. rare diseases)
• priority 2 (e.g. HIV)
• priority 3 (e.g. diabetes)
• etc.
This design allows relative weighting of each priority
versus other, potentially competing priorities that may have
been established. Scoring is performed based on how well
the intervention to be appraised is aligned with the
respective priority. The output of this design can thus
quantitatively capture the contribution of priorities (in
contexts where such have been established) to the value of
an intervention. In addition, this design allows addressing
variability in country or institution policies with respect to
prioritization of specific disease areas.
3.3 Normative Contextual Objectives
and Qualitative Criteria
These criteria cannot be operationalized on a universal
basis and are therefore appraised qualitatively in the gen-
eric framework [37]. As illustrated in the section above,
when adapting the framework to a given context, objectives
can be more closely defined and made operationalizable
into quantitative criteria, thereby allowing their integration
into the quantitative appraisal.
The objective of Aligning with the Mandate and Scope
of the Healthcare System rests upon the principle of
beneficence and utility, and its inclusion in the framework
ensures that this is explicitly considered in each appraisal
[36, 37]. The principal mandate of healthcare is to restore
and maintain normal functioning [68], and interventions for
rare diseases with serious health effects are generally
aligned with this mandate.
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This objective of Aligning with the Common Goal (i.e.
the health of patients, populations, and healthcare systems)
rather than with special interests corresponds to the rea-
sonableness condition of the Accountability for Reason-
ableness framework [23, 24], which demands that decisions
be based on relevant and mutually acceptable reasons [36].
Awareness of stakeholder pressures and barriers helps
ensure that decisions are fair-minded and not unduly
influenced by special interests [37]. For rare diseases,
several organizations exist that inform, support, and
advocate for patients [47, 48, 54, 62, 65]. While these are
important to bring real-life patient perspectives to decision
making, a balanced approach needs to be exercised for fair
allocation of resources across populations in need.
Although reducing Environmental Impact is a universal
normative objective, it currently does not play a significant
role in healthcare decision making (although many deci-
sion makers think that it should [28]), and is thus appraised
qualitatively, but could be incorporated into the quantita-
tive (universal) part of the framework in a given context
[37]. Due to their rarity, the environmental impact of rare
disease treatments is expected to be low.
3.4 Contextual Feasibility Objectives
and Qualitative Criteria
Some interventions may be desirable from a normative
point of view, but not feasible in a given context.
Consideration of Affordability and Opportunity Costs,
i.e. resources or existing interventions that may be forgone
if a new intervention is adopted, is aligned with the prin-
ciple of efficiency and utilitarianism (maximize health
resources) [43], which comes into play at both the patient
and societal levels [36, 37]. While the normative aspect of
economic considerations (i.e. favorable economic conse-
quences) is included in the quantitative (universal) part of
the framework, affordability and opportunity cost consid-
erations require a financial/budgeting exercise to determine
feasibility in a given context [37]. For rare diseases, this
reflects on whether resources foregone in other disease
areas (e.g. more common diseases) are significant in the
context of system-wide healthcare economics [56].
The ability of a healthcare system to ensure appropriate
use of a new intervention and realize its potential benefit
within the system’s capacity, depends on infrastructure,
organization, skills, legislation, barriers, and risk of inap-
propriate use [37]. Relevant for rare diseases is to ensure
that specific skills, infrastructure, and surveillance
requirements (e.g. patient registries, monitoring) and the
ability to reach remote populations are systematically
considered [3, 58, 60].
The political, historical and cultural context is important
to consider in appraisals. This includes the legal
framework, such as, for example, the Equality Act, under
which the NICE is required to avoid discrimination based
on protected characteristics, and the Human Rights Act,
under which it must consider implications for human rights
[84]. This objective also covers the impact of the inter-
vention on innovation and research, an important aspect for
rare diseases, as research in this area was shown to advance
understanding of pathophysiology, broadly contributing to
the development of knowledge [56]. Precedence is another
important consideration in coverage decision making in the
rare disease field, as in other therapeutic areas.
3.5 Hypothetical Example for Application
of the Adapted Framework
Table 2 shows an example of the application of the adapted
framework in two appraisal contexts: if population priori-
ties have not been established (context A), they are not part
of the quantitative model and are considered qualitatively.
In contrast, in a context in which population priorities have
been explicitly defined (context B), these are incorporated
into the quantitative model. In this case, the appraising
committee must decide how much relative weight they will
trade off from the other domains to ‘population priorities’
and how they will weigh the priority ‘rare diseases’ against
other priorities established in their context (Table 2a).
Now let us consider assessment of a hypothetical
intervention X for a rare condition Y by the same com-
mittee (Table 2b). Committee members assign a perfor-
mance score for each criterion that expresses their
judgment of the available evidence, as shown in the
example. Scores are standardized and multiplied by the
normalized weights (in Table 2a) to calculate the contri-
bution of each criterion to the value of intervention
X (Table 2b). The overall value estimate can then be used
to rank interventions across disease areas. In this hypo-
thetical example, inclusion of ‘population priorities’ in the
quantitative part of the model increases the value estimate
of X due to its full alignment with the rare disease priority
and the relatively high weight the committee has assigned
to this criterion. The committee also qualitatively considers
what impact contextual criteria may have on the value of
intervention X, which may impact its ranking of interven-
tion X. If priorities have not been included in the quanti-
tative value estimate, their potential impact can be captured
qualitatively and may affect ranking.
4 Discussion
In this study, we analyzed the EVIDEM framework from the
perspective of issues raised by rare diseases and developed it
further in response to these issues. The adapted EVIDEM
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framework provides an operationalizable platform to inte-
grate individual and social values, competing ethical
dilemmas, and uncertainty, which are particularly chal-
lenging in appraising interventions for rare diseases. The
addition of subcriteria to further differentiate disease
severity, disease-specific treatment outcomes and economic
consequences of interventions, inclusion of negative scoring
scales for all comparative criteria, and integration of a
methodology to further incorporate context-specific popu-
lation priorities and policies makes the EVIDEM framework
particularly responsive to rare diseases, whilemaintaining its
applicability across disease areas.
Development of the EVIDEM framework involves con-
tinuous research and development on handling of uncer-
tainty, which is particularly pertinent to the context of rare
diseaseswhere ethical dilemmas and variations in judgments
and perspectives are challenging for the healthcare com-
munity [25–27]. Uncertainty in judgments on evidence can
be explored using score ranges [85]; uncertainty in weights
can be gauged through application of different weighting
techniques (e.g. pair-wise comparison) [30, 46, 75]; uncer-
tainty due to variability in individual perspectives (weights)
and judgments (scores) can be assessed through standard
measures of statistical dispersion [25–27, 32, 33]; uncer-
tainty due to model structure can be explored by modifying
the structure, e.g. eliminating the lowest weighted criteria
[86]; and reproducibility can be examined by repeating the
appraisal exercise (test–retest) [33, 87]. In this study, we
additionally developed a method to address variability in
country or institution policies with respect to prioritization of
specific disease areas. This method allows adapting the
framework according towhether or not explicit prioritization
policies exist and to examine the relative importance of
specific priorities.
In a survey of the Norwegian population, the notion that
‘‘Patients with rare diseases should have the same right to
treatment as others even if more expensive’’ found strong
support [51]. Similarly, in a UK survey, concern for fair-
ness exceeded concern for population health maximization
(i.e. utility theory), the guiding principle of the cost-ef-
fectiveness-based approach to prioritization [63]. Cost
effectiveness is not considered in current [16, 17] or pro-
posed rare disease frameworks [18–20, 68], and several
HTA agencies waive their requirement for cost-effective-
ness analysis for orphan drugs [13, 88]. Some propose
modifying the current cost-effectiveness paradigm by, for
example, assigning quality-adjusted life-year (QALY)
weights depending on disease prevalence [9] or different
willingness-to-pay thresholds for diseases with high ‘social
value’ [89]. However, people do not prioritize rareness but
severe, life-threatening diseases, with high unmet needs
and interventions that reduce reliance on informal care-
givers [63, 66]. These attributes, while characteristic of
many rare diseases [1], also apply to other disease areas.
Implicit in these proposals is the realization that there is a
need for a holistic definition of value, beyond the cost per
QALY, to guide appraisal of healthcare interventions.
In comparison to other proposed MCDA frameworks for
rare diseases, where selection of decision criteria was based
on a literature review, consultation with stakeholders, or
rationales [18–20], selection of decision criteria for the
EVIDEM MCDA framework is additionally explicitly
rooted in a comprehensive set of ethical principles as well
as MCDA design principles, which promotes thorough
exploration of the values underpinning appraisal. In addi-
tion, due to alignment with the ultimate common goal of all
healthcare stakeholders, i.e. identifying interventions that
are beneficial to the health of patients as well as to popu-
lations and healthcare systems (definition of most valuable
interventions), the design proposed here can be applied
system-wide across interventions and diseases, in distinc-
tion to other MCDA rare disease frameworks. System-wide
operationalization is further supported through fully
developed implementation methods, particularly the gen-
eric design of the scoring scales, which measure evalua-
tors’ judgment of the available evidence across types of
interventions and outcomes.
This approach is also in contrast to MCDA models that
are designed adhoc to address a specific decision problem,
with a discrete set of known options (i.e. interventions).
Such ad hoc models can be designed around these options
and their attributes, in terms of criteria selection and
scoring scales [46, 90–92]. Ad hoc models, while useful for
a circumscribed decision problem, are not adapted to the
resource allocation context in which decision makers need
to decide, in a consistent manner, whether any proposed
intervention provides sufficient value to be funded and
adopted into practice. In such contexts, decision makers
need a tool to measure value grounded in fundamental
principles that reflect the goals of the healthcare system
[93]. For example, such an MCDA tool, including decision
criteria such as incremental benefits, incremental total cost,
and quality of evidence, was proposed for Israel’s Public
National Advisory Committee [77]. In addition, EVIDEM
has been adapted and implemented in several jurisdictions
as a system-wide approach that encompasses all the aspects
of decisions for resource allocation [34, 35].
Decision making at its core involves the balancing of
ethical dilemmas. Aiming to maximize the overall utility of
society (utilitarianism), few resources should be allocated to
therapies benefiting few individuals [56]. From a rights-
based perspective, access to appropriate healthcare is a right,
which is constitutionally established in some jurisdictions,
although its scope is open to interpretation [56]. Obviously, a
rights-based approach needs to be counterbalanced with
considerations of healthcare efficiency and sustainability.
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The multicriteria framework proposed here makes this bal-
ancing act explicit by defining decision criteria, each pro-
viding a distinct contribution towards the goal of healthcare.
Prioritization of rare diseases is made explicit and weighted
against other priorities and the goal of benefiting as many
people as possible, while taking into account disease sever-
ity, unmet medical needs and economic consequences. This
MCDA design incorporates the moral principles of benefi-
cence, nonmaleficence, respect for autonomy, and distribu-
tive justice, set forth by Beauchamp and Childress [39, 40]
and explicitly subscribed to by the NICE [94], and ensures
that these principles are actively considered in decision
making. Such approaches facilitate communication to
achieve workable resolution of ethical dilemmas across
stakeholders, which is necessary to promote the most valu-
able healthcare interventions to optimize health of patients,
populations, and healthcare systems.
5 Conclusion
The adapted framework measures value in its widest sense
and is responsive to rare diseases issues and policies. It
provides an operationalizable platform to explore values,
competing ethical dilemmas, and uncertainty in appraising
healthcare interventions.
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